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Abstract
T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive malignancy of thymocytes. Using 
a transgenic screen in zebrafish, thymocyte selection-associated high mobility box protein (TOX) 
was uncovered as a collaborating oncogenic driver that accelerated T-ALL onset by expanding the 
initiating pool of transformed clones and elevating genomic instability. TOX is highly expressed in 
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a majority of human T-ALL and is required for proliferation and continued xenograft growth in 
mice. Using a wide array of functional analyses, we uncovered that TOX binds directly to 
KU70/80 and suppresses recruitment of this complex to DNA breaks to inhibit Non-Homologous 
End Joining repair (NHEJ). Impaired NHEJ is well known to cause genomic instability, including 
development of T cell malignancies in Ku70 and Ku80 deficient mice. Collectively, our work has 
uncovered important roles for TOX in regulating NHEJ by elevating genomic instability during 
leukemia initiation and sustaining leukemic cell proliferation following transformation.
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) affects thousands of children and adults each 
year in the United States (1). There are many molecular subtypes of T-ALL, with those 
expressing the master transcriptional regulators TAL1 and LMO1/LMO2 comprising 60% of 
new diagnoses (2). Despite their wide differences in transcription factor activation and arrest 
at different stages of T cell development (1,3), T-ALL subtypes also commonly rely on 
similar oncogenic pathways for transformation. For example, MYC is now widely 
recognized as the dominant oncogenic driver in human T-ALL and is often activated 
downstream of NOTCH1 in a variety of T-ALL subtypes (4). Additional oncogenic drivers 
also likely collaborate with these potent oncogenes to elevate proliferation, alter tumor 
initiation, and expand early transformed T cell pools. For example, T-ALLs often harbor 
genomic deletion of p16INK4A, focal amplification of cMYB, and aberrant activation of 
TAL1 by genomic deletion of the SIL locus (1,2). Chromosomal translocations are also 
common in T-ALL and often result in mis-expression of oncogenic transcription factors or 
creation of novel oncogenic gene fusions that drive transformation and growth (2,5). Finally, 
recent studies have uncovered novel mechanisms to deregulate oncogenes in T-ALL through 
acquired small genomic insertions and deletions that drive high transcript expression and are 
acquired through aberrant DNA repair (6,7). Despite the high number of genomic 
aberrations found in human T-ALL and the supposition that these are driven by errant DNA 
repair, it has yet to be fully established how these genetic lesions are acquired and what, if 
any, DNA repair pathways may be altered in human T-ALL.
Non-homologous End Joining (NHEJ) is important for restoring genomic integrity to cells 
and provides a rapid and robust mechanism to re-ligate broken DNA strands to protect cells 
from undergoing apoptosis. Following the creation of a double-strand break (DSB), NHEJ 
repair can be initiated by recruitment of dimeric KU70/KU80 to sites of DNA damage (8). 
Other NHEJ factors are then recruited to the DNA lesion including DNA-dependent protein 
kinase catalytic subunit (DNA-PKcs), Artemis, XRCC4, Ligase IV and XLF/Cernunnos (9). 
These proteins facilitate repair by ligating the DNA ends and restoring DNA integrity. Not 
unexpectedly, impaired NHEJ often results in DNA translocations, inversions, and deletions 
that are characteristic of cancer (10). In fact, mice deficient in Ku70 or Ku80 have elevated 
genomic instability and develop T cell malignancies (11,12). Yet, KU70/KU80 and other 
NHEJ repair factors are not commonly deleted, mutationally inactivated, or hyper-
methylated in human T cell lymphoma or T-ALL, leading investigators to conclude that 
these pathways may not be dominant oncogenic drivers of T-ALL nor have important roles 
in regulating aberrant DNA changes seen at leukemia initiation. To date, mechanisms that 
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regulate elevated genomic instability and/or alter NHEJ repair in human T-ALL have not 
been established.
Using a transgenic screen in zebrafish, we have identified thymocyte selection-associated 
high mobility group box protein (TOX) as a collaborating oncogene that synergized with 
MYC and intracellular NOTCH1 to initiate early onset T-ALL, to expand the number of 
transformed clones, and to elevate genomic instability. TOX contains a single HMG box 
motif and has been suggested to be a transcription factor based solely by its homology with 
other HMG containing proteins. Yet, TOX shares remarkable conservation in protein 
sequence within its HMG box domain with well-known chromatin remodeling proteins that 
lack DNA binding specificity. Importantly, TOX regulates various aspects of T cell 
development (13–19) and is also genomically amplified in a subset of mouse and human T-
ALL (20). Work presented here has uncovered that TOX is transcriptionally activated by 
well-known T-ALL oncogenic transcription factors, including TAL1 and LMO1/2. 
Functional studies revealed that TOX regulates both proliferation and NHEJ in human T-
ALL and unexpectedly, these functions do not require binding of TOX to the chromatin. 
Rather, the HMG box of TOX binds directly to and inhibits KU70/KU80, impairing its 
recruitment to sites of DNA damage. Thus, one function of TOX is to lock human T-ALL 
cells in a state of dampened NHEJ repair. In total, our results provide a plausible cellular 
mechanism for elevated genomic DNA aberrations observed in human T-ALL and reveal 
additional roles for TOX in regulating proliferation after leukemic cell transformation.
RESULTS
TOX accelerates onset and malignant transformation in zebrafish MYC-induced T-ALL
To identify genes that collaborate with MYC to accelerate time to T-ALL onset, we 
completed a transgenic screen in zebrafish (Fig. 1a). Importantly, the zebrafish transgenic 
MYC-induced T-ALL model provides a robust and powerful tool to assess oncogenic drivers 
required to initiate T-ALL (21–24). This model shares remarkably similar molecular 
mechanisms of transformation with those found in mouse and human (21,23–25). Moreover, 
zebrafish T-ALL also harbor similar genomic DNA amplifications and deletions when 
compared with both human and mouse T-ALL (26,27), supporting conserved roles for 
genomic instability in driving T-ALL onset. In total, 27 genes were included in our screen 
based on being highly expressed, amplified, and/or mutationally activated in human T-ALL 
(Supplementary Table S1 and Supplementary Fig. S1a). Fish with fluorescent labeled 
thymocytes were followed for disease progression after 21 days of life, with leukemia being 
defined by >50% of the animal being overtaken by fluorescent-labeled T-ALL cells (24,26). 
From this analysis, 8 genes were identified that significantly shortened time to leukemia 
onset and increased disease penetrance (p<0.05, Log-rank statistic, Fig. 1b). As has been 
previously found using mouse models of T-ALL, BMI1 (28), HIF1α (29), IL7R mutations 
(30), and GFI1 (31) were identified as collaborating oncogenes in our screen, validating that 
similar genes and pathways drive leukemogenesis in zebrafish, mouse, and human (Fig. 1b). 
Our work also uncovered thymocyte selection-associated high mobility group box protein 
(TOX) as a novel collaborating oncogene that synergized with both MYC and activated 
intracellular NOTCH1 to induce T-ALL (Fig. 1b,c and Supplementary Fig. S1b). 
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Importantly, TOX alone was insufficient to transform thymocytes over the 150 days of 
observation.
To define a role for TOX in modulating T-ALL initiation and growth, we next undertook a 
cellular and molecular characterization of MYC and MYC+TOX expressing T-ALL. Both 
MYC and MYC+TOX- expressing T-ALL arose exclusively within the thymus (Fig. 1c), had 
similar lymphoblast morphology (Fig. 1f), and expressed T-cell markers, including higher 
TOX expression in double transgenic animals (Fig. 1g). Zebrafish MYC and MYC+TOX 
expressing T-ALLs expressed both tal1/scl and lmo2, confirming that TOX did not alter the 
subtype of T-ALL induced in zebrafish (Fig. 1g). EdU labeling experiments showed that 
proliferation rates also did not differ between MYC- or MYC+TOX-expressing T-ALL 
(p=0.34, Student’s t-test, n>9 T-ALL assessed per genotype, Fig. 1d). However, TOX-
expressing T-ALL had slightly fewer apoptotic cells when assessed by Annexin-V staining 
(Fig. 1e, p=0.012, ANOVA test). Finally, clonal analysis uncovered that MYC+TOX 
expressing T-ALLs had a dramatic 3-fold increase in TCRβ-recombined clones (MYC
+TOX, 7.4+/−1.5 clones compared to MYC, 2.4+/−0.3; p=0.0001, Mann Whitney test, Fig. 
1h and Supplementary Table S2). We conclude that TOX has prominent roles in 
transforming early thymic precursor cells and acts by expanding the overall pool of 
transformed clones at leukemia initiation.
TOX induces genomic instability in zebrafish T-ALL and MEFs
Human T-ALLs often harbor genomic deletions and amplifications indicative of genome 
instability and can be assessed clinically by quantitative changes in DNA content following 
propidium iodide (PI) staining and flow cytometry (32). This same methodology has been 
previously adapted to zebrafish T-ALL and is a rapid assay to identify leukemias with 
genomic copy number changes (25). As previously reported, 17% of zebrafish MYC-
induced T-ALL had increased DNA content (n=13 of 75) (25). By contrast, 47% of MYC
+TOX expressing T-ALLs had altered DNA content (n= 8 of 17, p=0.013, Fisher Exact test, 
Fig. 2a,b). TOX expressing T-ALLs also comprised a substantial fraction of leukemias that 
were hypodiploid, contrasting starkly with zebrafish MYC induced T-ALL where 
hypodiploidy has never been observed (p=0.006, Fisher Exact test). Together, these results 
show that TOX is a critical driver of genomic instability in zebrafish Myc-induced T-ALL.
To validate that TOX-expressing T-ALLs have elevated genomic instability and harbored 
alterations in genomic DNA, low-pass whole genome sequencing (WGS) was completed 
using Illumina Hiseq (0.5–1.0X genome coverage). Low-pass WGS can effectively detect 
deletions and amplifications akin to array comparative genomic hybridization (array CGH). 
When compared to matched control tissue isolated from the same leukemic fish, all three 
MYC+TOX leukemias showed large-scale genomic variations including deletions, gains, 
and amplifications (Fig. 2c,d and Supplementary Table S3). No recurrent lesions were 
identified in all three of the TOX+MYC expressing T-ALLs (Supplementary Table S3), 
indicating that TOX does collaborate with a specified set of amplifications or deletions to 
drive transformation, but rather TOX is likely a general modulator of genomic instability. 
Three Myc-induced T-ALLs were also analyzed by WGS, confirming DNA content changes 
identified by FACs and overall less DNA copy number aberrations when compared with 
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TOX expressing T-ALLs (Fig. 2d and Supplemental Table S3). Taken together, these results 
independently confirm that TOX imparts elevated genomic instability to zebrafish T-ALL 
cells.
To further assess a role for TOX in regulating genomic instability, TOX was transfected into 
mouse embryonic fibroblasts (MEF) cells and chromosomal abnormalities were assessed by 
metaphase spread (Fig. 2e,f). This analysis revealed that TOX significantly elevated genomic 
instability that was indicative of impaired NHEJ including elevation in unrepaired 
chromosome breaks and loss/gains of chromosome arms (p=0.005, Two Tailed Student’s t-
test; Fig. 2f). MEF cells that expressed a mutant form of TOX that lacked the HMG box, as a 
result of deletion of amino acids 261–339, also did not exhibit elevated genomic instability 
when compared with control treated cells (p=0.15, Student’s t-test). These data further 
support a role for TOX in elevating genomic instability and suggest prominent roles for the 
HMG box domain in regulating this process.
TOX is expressed in a majority of human T-ALL and is regulated by the TAL1/MYB 
transcriptional complex
To determine the extent of TOX expression in human T-ALL, we next analyzed transcript 
expression in a wide array of human cancer cell lines and uncovered that TOX was highly 
expressed in human T-ALL (Fig. 3a). This observation was extended to primary T-ALL 
patient samples, showing that TOX transcripts were highly expressed in human primary T-
ALL when compared to normal marrow, irrespective of molecular subtype classification 
(n=157 of 165 primary T-ALL express high transcript levels of TOX, Fig. 3b and 
Supplementary Fig. S2a,b). TOX protein expression was also assessed by Western blot 
analysis and showed that TOX was expressed in both human T-ALL cell lines and primary 
patient samples (n=10, Fig. 3c and Supplementary Fig. S2c,d). FACS analysis confirmed 
high expression of TOX at single cell resolution in a large fraction of primary human T-
ALLs (Fig. 3d,e). By contrast, TOX protein was detected at lower levels in human 
thymocytes and B-ALL (n=5).
Given that TOX is highly expressed in a large fraction of human T-ALL and yet only 
amplified in a small subset of human leukemias (20), we next investigated how TOX might 
be transcriptionally regulated in malignant T cells. High levels of H3K27ac occupancy are 
associated with recruitment of mediator and master transcription factors, which define 
stretch/super enhancers that ultimately drive high transcript expression (33,34). Genomic 
analysis uncovered elevated H3K27ac occupancy near the TOX locus in human T-ALLs but 
not immature and mature T-cell subsets or CD34+ marrow cells (Fig. 3f). Super-enhancer 
analysis revealed two prominent genomic regions that drive high transcript expression in 
human T-ALL cells, but were not found in normal thymocytes or mature T cell subsets 
(Supplementary Table S4). Further analysis of H3K27ac peaks revealed that super-enhancer 
#2 contained both the mediator complex and master T-ALL transcription factors including 
TAL1, MYB and GATA3 (Fig. 3g). Knockdown of these factors and additional members of 
the TAL1 complex including HEB and E2A, led to significant reduction in TOX transcript 
expression in human T-ALL cells (Fig. 3h). We conclude that high TOX transcription is 
regulated, at least in part, by super-enhancer regulation in human T-ALL.
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TOX regulates human T-ALL growth, proliferation, and apoptosis
To assess the consequences of TOX loss of function, HPB-ALL, CCRF-CEM, and MOLT-4 
human T-ALL cells were transduced with shRNAs against TOX and compared with 
scramble control shRNA. Following stable knockdown of TOX using independent shRNAs, 
all three T-ALL cell lines had reduced viability and overall growth when assessed by Cell 
Titer-Glo (Fig. 4a,b). EdU proliferation analysis showed that shTOX knockdown T-ALL 
cells exhibited a marked disruption of cell cycle, with arrest of cells in S-phase and overall 
reductions in cycling G2/M cells (Fig. 4c). TOX shRNA knockdown cells also had higher 
levels of apoptosis when assessed by Annexin-V/PI staining when compared with control 
cells (p<0.02, Student’s t-test, Fig. 4d and Supplementary Figure S3). These results show 
that TOX has major roles in regulating human T-ALL cell growth and leukemia 
maintenance, impacting both cell cycle and apoptosis.
To extend our findings to the in vivo setting, human HPB-ALL and CCRF-CEM knockdown 
cells were transduced with luciferase and assessed for growth in NOD/Scid/IL2Rγ null 
mice. TOX knockdown cells exhibited significantly reduced xenograft growth by 21 days 
when compared with control shRNA treated cells (Fig. 4e–j). Together, these data show that 
TOX also has important roles in regulating continued growth and maintenance of human T-
ALL cells in vivo.
TOX binds directly with KU70/KU80 through the HMG box domain
To develop hypotheses about how TOX might be regulating transformation, we sought to 
identify TOX binding partners. Specifically, endogenous TOX antibody pull-down 
experiments were performed in human HPB-ALL, MOLT4, and Jurkat T-ALL cells and 
interacting factors identified through liquid chromatography–mass spectrometry (LC-MS/
MS). Following separation of proteins on an SDS-page gel, prominent protein bands were 
detected in the TOX pull down cell lysates from HPB-ALL cells but not the IgG control 
cells (Supplementary Fig. S4). These bands were excised and analyzed by LC-MS/MS. 
From this analysis, KU70 and KU80 were identified as TOX binding factors (Supplementary 
Table S5a). Additional LC-MS/MS experiments performed in MOLT4 and Jurkat cells 
confirmed the KU70/KU80 interaction with TOX using analysis of total protein eluates 
obtained following endogenous TOX immunoprecipitation (Supplementary Table 5b). In 
these experiments, KU70 and KU80 exhibited a remarkable >22-fold enrichment over IgG 
control pull down cells, independently verifying TOX interaction with KU70/KU80.
To confirm Ku70/KU80 protein interactions identified by mass spectrometry, TOX 
immunoprecipitation was performed in the presence and the absence of DNase I and 
Western blot analysis completed with KU70 and KU80 specific antibodies in all three 
human T-ALL cell lines. DNase I treatment ensured that interactions of TOX and KU70/
KU80 did not result from binding common genomic DNA fragments (Fig. 5a). As was seen 
by the IP-mass spectrometry experiments, TOX interacted with KU70/KU80 in human HPB-
ALL, CCRF-CEM and MOLT-4 human T-ALL cell lines (Fig. 5a and Supplementary Fig. 
S5a). Reciprocal immunoprecipitation using the KU70 antibody confirmed specificity of the 
interaction (Fig. 5a, right panel). Consistent with our LC-MS/MS experiments, Western blot 
analysis also revealed that late acting NHEJ factors including XRCC4 and DNA Ligase IV 
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did not pull down with TOX (Fig. 5b), showing that the interaction of TOX with KU70/
KU80 was limited to the dimeric initiating complex that is first recruited to DNA double 
strand breaks (DSBs). In vitro binding assays using purified protein and performed in the 
absence of DNA confirmed a direct interaction between TOX, KU70, and KU80 (Fig. 5d 
and Supplementary Fig. S5b). By contrast, HMG deleted TOX was unable to bind KU70/
KU80 in in vitro binding assays (Fig. 5d), confirming a requirement for this domain in 
regulating the TOX protein:protein interaction with dimeric KU70/KU80.
Endogenous antibody pull down and in vitro binding assays showed the HMG box motif 
was responsible for protein:protein interactions with KU70 and KU80 and did not require 
DNA binding; thus, we wondered if, like other HMG group box containing proteins, TOX 
bound chromatin. Cell fractionation studies were performed in human HPB-ALL T-ALL 
cells and identified that TOX was highly expressed in the nuclear fraction and to a lesser 
degree to the cytoplasm; yet TOX did not bind to chromatin (Fig. 5c). Irradiation of cells 
induces large amounts of DNA damage and facilitates recruitment of repair enzymes to 
DNA breaks. Despite high dose irradiation of human T-ALL cells, TOX was still not 
recruited to chromatin even after 60 minutes following 3Gy irradiation treatment (Fig. 5c 
and Supplementary Fig. S5c). We conclude that TOX binds directly to KU70/KU80 through 
its HMG box domain and that this protein:protein interaction does not require DNA binding.
TOX inhibits DNA repair by suppressing recruitment of NHEJ factors to DSBs
Given the prominent roles for KU70/KU80 in regulating NHEJ and subsequently genomic 
instability (11,12) and that TOX over expression in zebrafish T-ALL and MEFs lead to 
genomic instability, we hypothesized that TOX might be an inhibitor of KU70/KU80 
function and thus affect NHEJ repair. Full-length TOX or deletion mutants that lack the NLS 
or HMG box domain were stably expressed in 3T3 fibroblast cells (Fig. 5e and 
Supplementary Fig. S6a). Cells were then transfected with linearized plasmid that contained 
a DNA DSB between the promoter and the GFP coding sequence, where GFP is expressed 
only following successful DNA repair. Cells expressing full-length TOX exhibited a 
remarkable 54+/−4.5% reduction in DNA repair when compared with control cells (Two 
tailed Student’s t-test, p=0.0004, +/− STD, Fig. 5e), while 3T3 cells expressing TOX 
deletion mutants that lack the HMG box or nuclear localization domain did not have altered 
NHEJ. Epistasis experiments revealed that when both KU70 and KU80 were expressed 
together, NHEJ was fully restored to TOX expressing cells (Fig. 5f). By contrast, expression 
of either KU70 or KU80 alone was not sufficient to restore NHEJ in TOX expressing cells 
(Fig. 5f). Suppressed NHEJ was also observed in 3T3 cells transfected with red fluorescent-
protein fusions of mRuby2 with full-length TOX but not when fused with deletion mutants 
that lack the HMG box domain (Fig. 5g). Imaging studies verified that both full-length TOX 
and HMG box deleted TOX were predominantly localized to the nucleus (Fig. 5g) while the 
NLS mutant was localized to the cytoplasm (Supplementary Fig. 6b).
To directly assess if TOX modulates recruitment of KU70/KU80 to the sites of DNA repair, 
3T3 fibroblasts were transfected with KU80-GFP and mRuby2, mRuby2-TOX or mRuby2-
ΔHMG, subjected to UV laser microirradiation-induced DNA damage, and assessed for 
KU80-GFP recruitment to DSBs (Fig. 5h). Cells expressing full-length TOX exhibited 
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significantly reduced recruitment of KU80-GFP to DNA breaks (p<0.05, Student’s t-test), 
while cells that expressed mRuby2-ΔHMG efficiently recruited KU80-GFP to sites of DNA 
damage with similar kinetics to control cells. mRuby2-TOX and fusions with HMG deleted 
TOX were not recruited to microirradiation induced breaks and remained nuclear localized 
throughout these experiments. Impaired recruitment of NHEJ pathway regulators to sites of 
DNA damage was independently confirmed using XRCC4-GFP (p<0.05, Student’s t-test, 
Fig. 5i). These experiments show that TOX sequesters KU70/KU80 away from sites of 
active DNA repair.
TOX loss of function in human T-ALL leads to elevated NHEJ repair
We hypothesized that TOX might lock human T-ALL cells in a state of dampened DNA 
repair, with the prediction that loss of TOX should elevate NHEJ repair. Stable knockdown 
or shRNA expressing control cells were transfected with linearized plasmid that contained a 
DNA DSB between the promoter and the mCherry coding sequence, with fluorescence only 
being detected following successful DNA repair. Plasmid based repair assays showed that 
HPB-ALL, CCRF-CEM, and MOLT4 T-ALL cells all exhibited enhanced NHEJ repair 
following stable TOX knock down using independent shRNAs (Fig. 6a–f and Supplementary 
Fig. S7; p<0.05, Student’s t-test). Similar results were obtained using stable integration of 
the Traffic Light Reporter (TLR). The TLR assay reads out NHEJ repair via RFP expression 
following induction of a DSB using tamoxifen-inducible I-SceI restriction enzyme (35). 
These experiments showed that NHEJ repair was greatly increased following TOX 
knockdown in CCRF-CEM cells, exhibiting a striking increase in NHEJ following TOX-
depletion (p=0.0001, Two-tail Student’s t-test, Fig. 6g,h).
To independently confirm a role for TOX in modulating DNA DSB repair, we next assessed 
the kinetics and localization of 53BP1 and γH2A.X in irradiated CCRF-CEM and HPB-
ALL T-ALL cells following stable knockdown of TOX. 53BP1 and γH2A.X are recruited to 
DNA following induction of DSBs and their kinetics can be measured to quantify resolution 
of the breaks following γ-irradiation (36). Using this strategy, we found that TOX 
knockdown led to significantly faster DNA break resolution in human T-ALL cells following 
3Gy irradiation (Fig. 6i,j; Supplementary Fig. S8; p<0.001, Student’s t-test). The overall 
numbers of foci were also reduced at many early time points reflecting ongoing and faster 
repair in TOX depleted cells following irradiation-induced DSB damage. Similar results 
were also seen in irradiated HPB-ALL cells (Supplementary Fig. S8; p<0.001, Student’s t-
test). Together, our data indicate that TOX negatively regulates the NHEJ pathway in human 
T-ALL and that human T-ALLs are locked in a state of dampened DSB DNA repair 
(Supplementary Fig. S9).
DISCUSSION
Our work has uncovered TOX as a novel collaborating oncogenic driver in T-ALL with 
important roles in both leukemia initiation and maintenance. TOX is amplified in a small 
subset of mouse and human T-ALL and was included in our screen based on these results 
(20). Yet, our work uncovered that most human T-ALLs express high levels of TOX and that 
this high transcript expression largely results from super enhancer regulation by well-known 
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T-ALL transcription factors including TAL1 and LMO1/2. Thus, TOX does not commonly 
meet the criteria for being a classically-defined oncogene which are activated by 
translocation, amplification or activating mutations, but rather TOX is expressed in 
developing T-ALL cells by oncogenic transcription factors, locking leukemia cells both in a 
state of heightened proliferation and dampened DNA repair. Importantly, TOX also had 
unexpected roles in regulating leukemia initiation by expanding the pool of initiating clones 
and elevating genomic instability in the zebrafish T-ALL model. Experiments completed in 
MEF cells confirmed roles for TOX in inducing genomic instability and generating 
chromosomal aberrations. Finally, studies of human T-ALL and xenograft studies revealed 
additional roles for TOX in regulating continued leukemia maintenance by specifically 
regulating cell cycle proliferation and apoptosis. These results are in keeping with known 
roles for TOX in regulating cell cycle in primary Sezary cells and Cutaneous T-cell 
Lymphoma where TOX knockdown led to cell cycle arrest and secondarily cell death (37). 
Collectively, our work has identified TOX as a new collaborating oncogenic driver in T-ALL 
and which likely exerts important and diverse functional effects in a large fraction of human 
T-ALLs.
Because TOX had been previously shown to regulate proliferation in primary Sezary cells 
and Cutaneous T-cell Lymphoma (37), our studies focused on uncovering additional roles 
for TOX in regulating DNA repair pathways. Remarkably, our endogenous TOX pull-downs 
and subsequent LC-MS mass spectrometry analysis uncovered potent interactions between 
TOX and KU70/KU80, prompting further investigation into roles for TOX in regulating 
DNA repair and NHEJ. Loss of NHEJ repair genes in mice are well-known to cause elevated 
genomic instability and cancer. For example, KU70 and KU80 deficiency in mice results in 
genomic instability and predisposition to T cell malignancy (11,12). Yet, genetic loss of 
KU70 or KU80 or disruption of other NHEJ factors has not been implicated as a major 
tumor suppressor pathway in human T-ALL. Rather our work has shown that TOX acts as a 
negative regulator of KU70/KU80 function to alter NHEJ repair and to elevate genomic 
instability. Remarkably, TOX remains highly expressed in fully malignant human T-ALL 
and locks leukemia cells in a state of dampened NHEJ repair, an observation confirmed 
using a wide array of DNA repair assays performed directly in human T-ALL cells. Even 
more remarkable is that TOX performs this function by directly binding KU70/KU80 and 
does not require binding to chromatinized DNA. Perturbations in NHEJ result in the creation 
of deletions, amplifications, transversions, and translocations that impart growth advantages 
to early transformed cells and drives cancer initiation. Thus, it is not surprising that 
mutations in DNA repair proteins can alter NHEJ and are predisposing to cancer. Our work 
strongly suggests that TOX may be such a factor in T-ALL.
Our results also suggest the existence of a new class of HMG group box proteins that 
function without binding chromatinized DNA. Indeed, endogenous chromatin 
immunoprecipitation studies and DNA-free in vitro binding assays show that TOX does not 
bind to chromatin. Rather, the HMG box domain of TOX is required for protein:protein 
associations with KU70/KU80 and functionally impairs recruitment of NHEJ factors to 
breaks. TOX contains a single highly conserved HMG box motif that is structurally distinct 
from both class I and II HMG box group containing proteins (38). Class I HMG box group 
proteins are transcription factors and contain a single HMG box that binds DNA in a 
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sequence-specific manner. These transcription factors include the TCF/LEF1 and SOX 
family members and have important roles in regulating a wide array of developmental and 
cancer processes (39). By contrast, class II group proteins contain two DNA-binding motifs, 
bind chromatin in a sequence agnostic manner, and have important roles in modifying DNA 
structure. For example, HMGB1 modulates nucleosome structure and alters transcription by 
looping chromatinized DNA to facilitate interaction of transcription factors with enhancer 
elements (40). HMGB1 also regulates a multitude of DNA repair pathways (41–43). For 
example, HMGB1 can enhance in vitro DNA ligase activity, by bringing DNA ends into 
close proximity (44). Yet, to date, functional roles for HMGB1 and other class II HMG 
group box proteins in regulating DNA bending and repair necessarily require binding to 
chromatin.
Together, our data suggest that TOX may represent the first of a novel class of HMG 
proteins that function, at least in part, by binding regulatory proteins through their HMG box 
and regulating NHEJ repair. Given the prominent role TOX has in T cell development and its 
coordinated regulation coincident with TCRβ and TCRα rearrangement in mice, it is also 
possible that TOX may have roles in development including regulation Recombination-
Activating Gene (RAG)-mediated recombination. Moreover, TOX is highly and specifically 
expressed in human T cell malignancies while its related family members TOX2, TOX3, and 
TOX4 are differentially regulated in a variety of human cancers including Breast cancer, 
Ewing sarcoma, Multiple Myeloma and Small Cell Lung cancer (45–47). Many of these 
tumors are well known to have elevated genomic instability and harbor characteristic lesions 
that are associated with impaired NHEJ. It will be important to assess whether these closely 
related TOX family members share molecular functions in regulating cell proliferation, 
transformation and genomic instability in a wider range of human cancers.
Materials and Methods
Transgenic DNA expression constructs
DNA constructs used to generate transgenic zebrafish included rag2:mCherry (23), 
rag2:MYC (21) and rag2:NICD (24). All genes, except FNBP1, GFI1, GITR, BMI1 and 
TOX, used in this screen were obtained from hORFeome (48). IL7R constructs were created 
using site-directed mutagenesis. Full-length ORFs for human FNBP1, GFI1 and GITR were 
obtained by PCR-amplification of cDNA derived from human T-ALL cells. Zebrafish TOX 
was amplified from the cDNA of 1 to 5-day-old Tu/AB zebrafish and subcloned into pENTR 
gateway system (Life Technologies). PCR primer sequences can be found in Table S6. All 
genes were transferred into the rag2 promoter destination vector using LR clonase II (Life 
Technologies).
Creation of zebrafish T-ALL
Plasmids were linearized with NotI or XhoI and purified. Mosaic transgenic animals were 
generated as previously described (22). 40 ng/μL rag2:mCherry was mixed with 40 ng/μL of 
rag2:Myc or rag2:NICD and 40 ng/μL rag2:experimental gene and micro-injected into one-
cell stage Tu/AB embryos. Animals were scored for fluorescent-labeled thymi at 21 and 28 
days of life and then followed weekly for disease onset. Leukemic fish are defined by >50% 
Lobbardi et al. Page 10
Cancer Discov. Author manuscript; available in PMC 2018 November 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
of their body being infiltrated with fluorescent T-ALL cells as previously described (24,26). 
Zebrafish experiments were approved under animal protocol 2011N000127 (MGH).
Clonality, proliferation, apoptosis and DNA content
Proliferation was assessed using the Click-IT EdU kit (Life Technologies) according to the 
manufacturer protocol. A pulse of EdU was performed following cell harvest and completed 
for 1h at 28.5°C. Zebrafish T-ALL cells were assessed for apoptosis using DAPI and Alexa 
Fluor 647-conjugated AnnexinV (Life Technologies). Numbers indicate the mean of ≥9 
biological replicates +/− the s.e.m. For DNA content, 1×106 zebrafish T-ALL cells were 
permeabilized in 70% ice-cold Ethanol for >2hrs at −20°C. Cells were then incubated in 
500μL of a solution containing 50μg/mL PI, 1mg/mL PureLink RNase and PBS-1% BSA 
for 30 minutes at 25°C. EdU-stained cells, AnnexinV-stained cells and DNA content were 
then analyzed using LSR II or Fortessa Flow Cytometer (BD Biosciences). The DNA index 
quantifies differences in total DNA in the test cell population in relation to that in normal 
diploid cells, comparing maximal G0/G1 peak heights between samples when assessed by 
FACs. A DNA index of 1.0 is indicative of normal diploid cells.
The zebrafish TCRB recombination assay was first described by Blackburn et al. (24). 
Briefly, RNA was extracted from FACS-sorted T-ALL cells, made into complementary 
DNA, and PCR was performed utilizing each Vb and Cb primer (51 variable spanning PCR 
primers and 2 constant regions). A semi-nested PCR was completed using 1 μl of the PCR 
product and resolved on a 2% agarose gel. From this analysis, we can quantify the overall 
numbers of clones contained within the leukemia (24,26).
RT-qPCR was performed on bulk leukemias (n=5 fish/genotype) and compared with FACs 
sorted rag2:GFP+ thymocytes (n=2 samples). Samples were run in triplicate, with error bars 
representing the s.e.m of compiled data from all replicates and experimental samples.
Genomic DNA sequencing of zebrafish T-ALL
Zebrafish genomic DNA was extracted from T-ALL cells using a solution containing 10mM 
Tris-EDTA, 0.2% SDS, 200mM NaCl and 200μg/mL Proteinase K following incubation at 
50°C for >16hrs. The next day, the Proteinase K was heat-inactivated at 95°C for 10min. 
The gDNA extract was then purified using genomic DNA clean and concentrator (Zymo). 
Purified zebrafish gDNA was sheared and made into a library by the MGH Next generation 
sequencing core. Next-generation sequencing of zebrafish gDNA from MYC, MYC+TOX 
and WT samples was performed using Illumina HiSeq Instrument. Following alignment to 
the Zv9 genome using BWA (49), analysis of large-scale genomic variants using HMMCopy 
(50). In addition, a direct comparison of mutant and WT coverage was performed by 
calculating read coverage within non-overlapping 10 Kb windows across the genome. The 
log-log scatter plots of the resulting read counts from leukemias were compared to the 
corresponding WT tissue isolated from the same fish.
Metaphase spread on mouse MEF cells
MEF cells were transfected with control, full-length TOX, and dHMG box containing TOX. 
After 48h post transfection, MEF cells were incubated with 100ng/μL KaryoMax Colcemid 
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for 90min (Life Technologies), washed and incubated for 18 min with 0.075M KCl. 1mL of 
a 3:1 Methanol:glacial acetic acid (fixative solution) was added to the chromosome 
preparation and centrifuged 10min at 400g, 4°C. The pellet was washed 2 times with 3mL of 
fixative solution and resuspended in 1mL of fixative solution. Chromosomes were spread on 
microscope slides and dried 10min at room temperature. DAPI Fluoromount-G (Southern 
Biotech) was added to each slide and imaged. At least 50 nuclei are counted per condition 
and per experiment. Experiments were replicated 3 independent times.
Gene expression analysis of TOX in human T-ALL
TOX transcript expression was assessed in human cell lines using the Cancer Cell Line 
Encyclopedia (45) (GSE36139) and in human T-ALL patient samples using the program R2: 
Genomics Analysis and Visualization Platform (http://r2.amc.nl). Data sets included 
normalized gene expression for healthy bone marrow (GSE13159) and human leukemia 
samples comprising the “Mixed Leukemia – MILE – 2004” (GSE13159) and “Tumor ALL 
(T) - Meijerink – 124” datasets (GSE26713). Statistical analysis and visualization was 
completed using Prism6.0. Whiskers plots have been utilized to visualize the data and are 
represented using the Tukey method. Primary human samples used in this work were 
collected under the IRB DFCI 05-001.
Protein lysates were extracted using RIPA buffer, quantified using Coomassie Plus Bradford 
protein assay (Pierce), and analyzed by Western blot analysis. Specifically, denaturated 
proteins were loaded on a 4–20% gradient gel (Biorad) and then transferred to a PVDF 
membrane (Biorad). Antibody staining was visualized using Amersham ECL Prime reagent 
(GE Healthcare) followed by analysis using a Fluor-S MultiImager (Biorad). Band intensity 
was quantified using the ImageJ software package. Human T-ALL cells were assessed by 
Western blot analysis using primary antibodies for α-TOX (1:1000 dilution, eBioscience), 
α-GAPDH (1:2500, #2118, Cell Signaling Technology), α-TAL1 (1:200, BTL73, EMD 
Millipore), α-LMO2 (1:200, sc-65736, Santa Cruz Biotechnology) and α-cleaved NOTCH1 
(1:1000, #4147, Cell Signaling Technology). The secondary antibodies used were HRP-
conjugated anti-rat IgG (1:2000, #7077, Cell Signaling Biotechnology), HRP-conjugated 
anti-rabbit IgG (1:2500, #7074, Cell Signaling Biotechnology) and HRP-conjugated anti-
mouse IgG (1:5000, G21040, Life Technologies).
Mouse xenografts and luciferase imaging
Human T-ALL cells were luciferized using the pLKO.1-luc-mKate (gift from Drs. 
Matthijssens and Van Vlierberghe, Ghent University, Belgium) and equal numbers of viable 
cells were injected into the flanks of six-week-old NOD/SCID/IL2rg null female mice 
(1×106 of viable cells per 200 μl). Mice were anesthetized by isofluorane and leukemia 
growth was monitored by bioluminescence imaging following subcutaneous injection into 
the loose tissue over the neck of 75mg/kg D-luciferin (Perkin Elmer) in 100 μl of PBS. 
Comparisons of leukemia size used an ANOVA test and Student’s T-test comparisons 
between control and treated cells. Mouse experiments were approved under animal protocol 
2013N000038 (MGH).
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ChIP-Seq analysis
Reads were aligned to the hg19 version of the human genome using bowtie (51) with 
parameters –k2 –m 2 –best –sam and –l set to read length. Wiggle files to display the density 
of reads relative to genomic loci were created with MACS (52) with parameters –w –S –
space=50 –nomodel –shiftsize=200 –keep-dup=1. The wiggle files were subsequently 
normalized to the millions of unique positions covered by reads. Wiggle files were displayed 
in the UCSC genome browser. Array file name used in this study are indicated in Table S6.
Super-enhancer identification
Super-enhancers were identified in two stages as described previously (34,53). First, 
constituent enhancers were defined as peaks of H3K27ac using MACS with two sets of 
parameters to account for focal amplifications: -p 1e-9–keep-dup=1 and –p 1e-9 –keep-
dup=all. Second, the union of these sets of peaks was used as input for ROSE, which stitches 
proximal enhancer constituents and ranks stitched enhancers by signal. ROSE was run with 
parameters –s 12500 and –t 1000 to stitch constituents within 12.5kb of each other and 
exclude constituents fully contained within +/−1kb from promoters of RefSeq genes.
Stitched enhancers were each assigned to the single expressed RefSeq gene locus whose 
transcription start site is most proximal to the center of the stitched enhancer. Genes were 
considered expressed if they were in the top 2/3 of all TSS when ranking by promoter 
H3K27ac density. RPM-normalized promoter H3K27ac density was calculated in 1kb 
windows center on TSSs using bamToGFF with parameters –e 200 –m 1 –r –d.
Immunoprecipitation and Western blot analysis
Immunoprecipitation was performed using 300μg of protein lysate along with 4μg of TOX 
antibody (GeneTex), KU70 antibody (ab3108, Abcam) or control rabbit IgG (Santa Cruz 
Biotechnology). Immunoprecipitation was completed in the presence of 30–40μL of 
Dynabeads Protein G (Life Technologies) and incubated for 16h at 4°C in Cell Lysis Buffer 
(Cell Signaling Technology). Beads were then washed 5 times and proteins were eluted 
using denaturating Laemmli, at 95°C for 10min. Denaturated proteins were loaded on a 4–
20% gradient gel (Biorad) for Western Blot analysis and then transferred to a PVDF 
membrane (Biorad). Antibody staining was visualized using Amersham ECL Prime reagent 
(GE Healthcare) followed by analysis using a Fluor-S MultiImager (Biorad). Band intensity 
was quantified by ImageJ. For DNase I treatment, EDTA- free lysis buffer was used to 
prepare cell lysates. MgCl2 was added to the final concentration of 0.4 mM. 2.5 μl of 5 
mg/ml DNase I were added to 500 μg of cell lysates. The digestion was performed by 
rotating at room temperature for 10 minutes. EDTA was then added to the final 
concentration of 5 mM to stop the nuclease reaction.
Primary antibodies were α-TOX (1:1000 dilution, eBioscience), α-KU70 (1:1000, ab92450, 
Abcam), α-KU80 (1:1000, #2753, Cell Signaling Technology), α-GAPDH (1:2500, #2118, 
Cell Signaling Technology), α-XRCC4 (1:200, sc-365118, Santa Cruz Biotechnology), and 
α-LIGASE IV (1:200, sc-271299, Santa Cruz Biotechnology). The secondary antibodies 
used were the same as described above.
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In vitro binding assay
TOX and ΔHMG were subcloned into pT7CFE1-NHis-GST-CHA plasmid using the BamHI 
and XhoI restriction enzyme sites. 4μg of each construct was then transcribed and translated 
using the 1-Step Human High-Yield mini IVT kit (Pierce). TOX proteins were purified using 
the MagneGST Protein Purification System (Promega) and interactions with KU70/KU80 
assessed on column. Specifically, 0.5μg–3μg of KU70/KU80 proteins (Abcam) were added 
to TOX bound beads. Following 2 hours of binding at 25°C, samples were washed 5-times 
using wash binding buffer supplied from the manufacturer (Pierce). TOX was cleaved from 
the beads using HRV3C protease (Pierce), purified away from beads, and the elution loaded 
on a 4–20% gradient gel for Western blot analysis. In vitro binding assays were performed 
three independent times.
Cell lines and Authentication
NIH3T3 and MEF cells were obtained from ATCC in 2012 and 2015, respectively and used 
within three months of receipt. Human T-ALL cell lines, MOLT-4, CCRF-CEM, HPB-ALL, 
JURKAT, DND-41, KE-37, KOPTK1, MOLT13, P12-ICHIKAWA, PEER were a gift from 
A. Thomas Look in 2012. Human HEK293T cells were ordered from ATCC in 2012. All 
human cell lines were authenticated at receipt and just prior to use in experiments using 
Small Tandem Repeat profiling and certified mycoplasma (MycoAlert Plus, Lonza, tested 
every 6 months).
Cell fractionation
Cell fractionation was completed essentially as described by the manufacturer (Subcellular 
Protein Fractionation kit, Pierce; 1×107 human T-ALL cells). However, one additional wash 
was utilized in each cell fraction. Protein fractions were quantified by Bradford assay and 
20μg–45μg of proteins were loaded on a 4–20% gradient gel for Western blot analysis. 
Primary antibodies were α-TOX, α-TUBULIN (1:500, ab4074, Abcam), α-SP1 (1:1000, 
#9389, Cell Signaling Technology), and α-H4 (1:1000, #2935, Cell Signaling Technology). 
The secondary antibodies used were the same as described previously. Cell fractionation was 
performed three times with similar results.
Transient assays for NHEJ in 3T3 cells and human T-ALL cells
For the NHEJ assay, DNA double strand break was made in pEGFP-N1 vector or a pCS2-
GW-mCherry by double-digestion with XhoI/BamHI and EcoRI/BamHI respectively, 
similarly to previous published work (54). When 3T3 cells were 70% confluent, they were 
transfected with control or TOX expressing vectors with or without KU70 and/or KU80. 
Cells were also transfected at the same time with linearized NHEJ reporter DNA into a 6-
well plate (TransIT-X2 reagent, Mirus Bio). For nucleofection experiments in human T-ALL 
cells, 5×105 cells were nucleofected with control or TOX expressing vectors along with 
linearized NHEJ reporter DNA. The Amaxa Cell Line Nucleofector kit L was used for HPB-
ALL and CCRF-CEM, while kit V was used for MOLT-4 (program A-030, Lonza). 48hrs/
72hrs post transfection/nucleofections, the cells were analyzed by flow cytometry counting 
the number of GFP or mCherry positive cells and normalized to the number of fluorescent 
reporter cells. These assays were performed three independent times in triplicate.
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Live cell imaging following micro-irradiation induced DNA damage
Human TOX or the HMG box deletion mutant were gateway-cloned into the pDest26 
expression vector (Life Technologies). mRuby was then subcloned in frame using SalI and 
BglII. pmRuby2, pmRuby2-TOX or pmRuby2-ΔHMG constructs were co-transfected into 
3T3 cells with KU80-GFP or XRCC4-GFP using electroporation (Neon transfection system, 
Life Technologies). 8–24 h later, cells were treated with Hoescht 33342 and subjected to 405 
nm laser-induced micro-irradiation and imaging as described previously (55). Images were 
processed and analyzed using Slidebook 5.0 software (Intelligent Imaging Innovations) and 
Adobe Photoshop CS6. Quantification of fluorescence intensity was measured within laser 
track regions and normalized to regions outside the track for each time point (> 15 cells 
assessed for each time point).
Lentivirus infection and Traffic Light Reporter assay
Sequences for each shRNA are provided in Supplementary Table 6. 2μg of pLKO-shTOX or 
pLKO-scramble (Addgene plasmid 1864) were cotransfected into HEK 293T cells with 2μg 
pCMV-dR8.91, 0.2μg pVSV-g and TransIT-LT1 reagent (Mirus Bio). Supernatants 
containing the lentivirus were collected, filtered, and added to T-ALL cell lines in the 
presence of 4μg/mL polybrene (Millipore). T-ALL cells were spinoculated at 2000g for 
90min at 32°C. 2 days post-infection, cells were selected by adding 6μg/mL puromycin 
(Invivogen). For the Traffic Light reporter assay, 2μg pCVL-TLR-Ef1a-BFP (Addgene 
plasmid 31481) (35) was cotransfected in addition to the previous plasmids. BFP positive 
cells were FACs sorted on the Aria Flow Cytometer (BD Biosciences). BFP positive, 
puromycin-selected cells were then nucleofected with tamoxifen-inducible I-SceI expressing 
vector (gift from Dr. Mostoslavsky, MGH). 24h post nucleofection, 200nM of Tamoxifen 
was added to the cells and incubated for 48h before FACs analysis. These experiments were 
repeated in triplicate and repeated twice.
Tandem mass spectrometry (LC-MS/MS)
Gel separated samples were alkylated with iodoacetamide and digested overnight at pH 8.3 
with sequencing grade trypsin (Promega). Peptide mixtures were analyzed by microcapillary 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) using the EASY-nLC 
nanoflow HPLC (Thermo Fisher Scientific) with a 75μm inner diameter × 15 cm length C18 
capillary column coupled to a hybrid Orbitrap Elite mass spectrometer (Thermo Fisher 
Scientific). The Elite was operated in data-dependent acquisition (DDA) mode (1 profile FT-
MS spectrum followed by 15 centroided IT-MS/MS spectra). The resolution was 60,000 in 
FT-MS mode and MS/MS spectra were read out at low resolution via CID in the Velos ion 
trap. The gradient consisted of 3–38% acetonitrile in 0.1% formic acid (FA) at a flow rate of 
300 nL/min for 75 min, 38–95% acetonitrile in 0.1% FA for 2 min and held at 95% 
acetonitrile in 0.1% FA at for 7 min followed by column re-equilibration for 10 min at 3% 
acetonitrile in 0.1% FA. MS/MS fragmentation spectra were searched for protein 
identification using the Mascot search engine against the reversed and concatenated 
SwissProt protein database (v7_2012).
Carbamidomethylation of Cys was set as fixed modification and variable modifications were 
oxidation of Met and deamidation of Gln and Asn. Precursor ion mass tolerance was set to 
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12 ppm and fragment ion mass tolerance was set to 0.8 Da. Two missed cleavages were 
allowed and the minimal length required for a peptide was six amino acids. Relative 
quantification of proteins was achieved through peptide spectral counting using Scaffold 4 
software. The peptide and protein false discovery rates (FDR) were set to 1.5%.
To confirm the results from identifying proteins from selected protein bands from SDS-
PAGE gels, the unfractionated sample of affinity enriched proteins was reduced and 
alkylated in solution basically as described previously (56). Proteins then were precipitated 
with chloroform-methanol, resuspended in 4 M urea/50 mM HEPES (pH 8.5) and digested 
using first endoproteinase LysC (Wako) and then sequencing grade trypsin (Promega). The 
generated peptides were analyzed by LC-MS2 in a 70 min gradient on an Orbitrap Fusion 
mass spectrometer equipped with an EASY-nLC 1000 autosampler/HPLC pump. The mass 
spectrometer was operated in a data-dependent mode with a full MS spectrum acquired in 
the Orbitrap followed by MS2 spectra acquired in the linear ion trap on the most abundant 
ions detected in the full MS spectrum. MS2 spectra were assigned using a SEQUEST-based 
(57) proteomics analysis platform (58) by searching against the human Uniprot sequence 
database. Peptide and protein assignments were filtered to a false discovery rate of < 1 % 
employing the target-decoy database search strategy (59) and using linear discriminant 
analysis and posterior error histogram sorting. Peptides with sequences contained in more 
than one protein sequence from the database were assigned to the protein with most 
matching peptides (58). Interacting proteins were assigned by the following criteria: 1) at 
least 10 independent peptides must be found in the TOX pull down samples and 2) there 
must be at least a 3 fold enrichment over IgG-pull down controls.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of Significance
TOX is a HMG box containing protein that has important roles in T-ALL initiation and 
maintenance. TOX inhibits the recruitment of KU70/KU80 to DNA breaks thereby 
inhibiting non-homologous end joining repair. Thus, TOX is likely a dominant oncogenic 
driver in a large fraction of human T-ALL and enhances genomic instability.
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Figure 1. TOX collaborates with MYC to accelerate T-ALL onset
(a) Schematic of transgenic screen. (b) Kaplan-Meier analysis (p<0.05, Log-Rank Statistic). 
Leukemic fish have >50% of their body overtaken by T-ALL cells. Number of animals 
analyzed per genotype is shown in parenthesis. (c) Images of T-ALL transgenic fish at 21, 
28 and 35 days post-fertilization (dpf). Asterisks denote auto-fluorescence. Arrowheads 
show leukemias initiating in the thymus. Scale bar equals 2mm. (d) EdU proliferation 
analysis of zebrafish T-ALL. Not significant (NS). +/− STD noted. (e) Annexin-V apoptosis 
staining as assessed by flow cytometry. Asterisk denotes p<0.05, Two-tailed Student’s t-test. 
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+/− STD noted. ≥9 primary T-ALLs were analyzed per genotype in d,e. (f) Cytospin 
showing lymphoblast morphology (n>5 leukemias/genotype analyzed). Scale bar is 20μm. 
(g) RT-qPCR gene expression comparing MYC and MYC+TOX expressing T-ALL (n=5 per 
genotype, run in triplicate) with sorted thymocytes isolated from rag2:GFP transgenic fish 
(purity >95%, viability >95%). *: p<0.05; ***: p<0.001, Two-tailed Student’s t-test. Not 
significant (NS). Error bars denote standard error of the mean. (h) Number of TCRβ clones 
per primary leukemia (MYC+TOX: n=9 animals; MYC: n=24 animals). Asterisk indicates 
p<0.05, Two-tailed Student’s t-test. Error bars denote standard error of the mean.
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Figure 2. TOX promotes genomic instability
(a) Flow cytometry analysis showing DNA content of zebrafish T-ALL (blue) compared to 
normal blood-derived DNA (red). Representative leukemias are shown with changes in DNA 
index noted (DI). 2n has a DNA index of 1. (b) Quantization of DNA content. Asterisk 
denotes p=0.013, Fisher Exact Test. (c) Genomic DNA alterations identified by whole 
genome sequencing. The log-log scatter plot represents read counts within non-overlapping 
window size of 10 kb across the genome comparing leukemia and control tissue from the 
same, representative animal. Amplifications found in the MYC+TOX leukemia are denoted 
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by the green circle. (d) Manhattan plot representing the copy number variation across the 
genome of a representative MYC (top) and MYC+TOX (bottom) expressing T-ALL. 
Regions of significant gain, amplification (AMPL), high level amplification (HLAMPL), 
and neutral 2N copy number (NEUT) noted. (e-f) Analysis of metaphase spreads from MEF 
cells infected with control (MOCK), full-length Wild-type TOX (TOX WT), or TOX that 
lacks the HMG box domain (TOX dHMG). Arrows denote chromosome abnormalities. (f) 
Quantification of cells with genomic abnormalities. >50 nuclei were counted per condition 
and replicated three independent times. Error bars denote standard deviation. *, p<0.05 and 
**, p<0.005, Student’s t-test. Not significant (NS).
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Figure 3. TOX is highly expressed in human T-ALL and transcriptionally regulated in a subset 
of leukemias by the TAL1/MYB complex
(a) TOX microarray gene expression from the Cancer Cell Line Encyclopedia. Box-and-
whisker plots denote median TOX expression (black line), the inter-quartile range (box) and 
1.5× the inter-quartile range (bars). (b) Volcano plot comparing gene expression between 
human T-ALL patient samples and bone marrow. (c) Western blot analysis of primary 
human leukemia (top) and T-ALL cell lines (bottom). The same thymus sample was run in 
lane 1, top and lane 2, bottom. (d) Flow cytometry analysis showing TOX expression in 
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primary human T-ALL compared with B-ALL. Control is T-ALL cells stained with 
conjugated IgG control antibody (ctr). (e) Quantification showing the percentage of TOX+ 
cells found in each patient sample (right panel, **, p=0.006, Two-tailed Student’s t-test). 
Mean and standard error of the mean are denoted. (f-h) TOX is associated with two distinct, 
H3K27 acetylated super-enhancers (SE) in human T-ALL. (f) ChIP sequencing of human T 
cells, CD34+ progenitor cells from the marrow (black peaks), and T-ALL cell lines (red 
peaks). Super-enhancer 1 (SE 1) is found in MOLT-3 and Jurkat, while SE 2 is found in all 
three human T-ALL cell lines. (g) Magnified view of SE 2 in Jurkat T-ALL cells showing 
super-enhancer occupancy by the TAL1/MYB complex. (h) TOX gene expression in Jurkat 
cells following knockdown of T-ALL transcription factors found within the H3K27 
acetylated super-enhancer (***, p<0.001; **, p<0.01; *, p<0.05, data set from GSE29179; 
+/− standard error of the mean denoted).\
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Figure 4. TOX is required for continued human T-ALL growth and maintenance
(a) Western blot analysis following stable shRNA knockdown in human T-ALL cells. 
Percent knockdown noted. (b) Cell viability following knockdown as assessed by Cell 
TiterGlo. (c) EdU proliferation analysis. (d) Annexin-V staining. Asterisks in b-d denote 
p<0.05, Student’s t-test. Xenograft studies performed with human HPB-ALL (e-g) and 
CCRF-CEM (h-j). (e,h) Flow cytometry analysis showing efficiency of TOX knockdown. 
(f,i) Luciferase bioluminescent imaging of representative animals engrafted at 0 days 
compared with 21 days. Scramble shRNA control (left flank) or shRNA-TOX #2 (right 
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flank). (g,j) Quantification of xenograft growth using two independent shRNAs. Not 
significant (NS), p<0.05 (*), p<0.01 (**), and p<0.001 (***), ANOVA test.
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Figure 5. TOX binds directly to the KU70/KU80 and inhibits Non-Homologous End Joining by 
suppressing recruitment of KU70/KU80 to sites of DNA damage
(a) TOX immunoprecipitation followed by Western blot analysis in HPB-ALL cells in the 
presence or absence of DNAseI treatment. The right panel shows the reciprocal 
immunoprecipitation using anti-KU70. (b) TOX immunoprecipitation followed by Western 
blot analysis for members of the NHEJ pathway. (c) Western blot analysis following cell 
fractionation in non-irradiated and 3Gy-irradiated HPB-ALL cells. TUBULIN, SP1 and 
Histone H4 (H4) are controls for assessing cytoplasmic, nucleoplasmic and chromatin 
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fractions, respectively. (d) In vitro binding of TOX (WT) or HMG-box (ΔHMG) deletion 
mutant with KU70/KU80 followed by Western blot analysis. Negative control was KU70/
KU80 added to beads and then purified in the absence of TOX (Neg. Ctr). Loading control 
contains only purified KU70/KU80 proteins (Load Ctr). (e) Western Blot analysis of 3T3 
cells following transfection with full-length TOX (+), ΔHMG (ΔH), or ΔNLS (ΔN). Below is 
the quantification of the NHEJ assay (NS: Not significant; ***, p<0.0001, Two-tailed 
Student’s t-test comparing experimental samples with control, +/− STD noted). (f) Western 
Blot analysis of 3T3 cells following transfection with full-length TOX, KU70 and/or KU80. 
Below is shown the quantification of the NHEJ assay (**, p<0.001, ***, p<0.0001, Two-
tailed Student’s t-test, +/− STD noted). (g) Confocal imaging of 3T3 cells transfected with 
mRuby2-fused constructs. Dashed lines denote nucleus as assessed by Hoechst stain (n>100 
cells/construct analyzed). The lower right panel shows the fluorescence-based NHEJ assay 
completed in 3T3 (*, p=0.03, Two-tailed Student’s t-test). +/− STD noted. (h,i) Quantitative 
assessment of recruitment of KU80-GFP (h) or XRCC4-GFP (i) to sites of UV laser-induced 
DNA damage in 3T3 cells. Asterisks denote significant differences (p<0.05, Two-tailed 
Student’s t-test). +/− STD noted. Representative fluorescent images of cells following laser-
induced damage are shown to the right.
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Figure 6. TOX loss-of-function increases DNA repair and accelerates the time to break resolution 
in human T-ALL cells
(a–f) Transient repair assays in HPB-ALL (a–c) and CCRF-CEM (d–f) cells that have 
shRNA knockdown. (a,d) Western blot analysis with percent knockdown noted. (b,e) Flow 
cytometry analysis of knockdown and control cells following transient fluorescence-based 
NHEJ assay. (c,f) Graphical summary of data. *, p<0.05; ***, p<0.001 when compared with 
control shRNA treated cells, Two-tailed Student’s t-test. (g) Western blot analysis of TOX 
expression in CCRF-CEM cells with stable TOX shRNA #2 or scramble control shRNA 
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knockdown used in the Traffic Light Reporter assay. (h) Flow cytometry analysis of CCRF-
CEM cells stably integrated with the Traffic Light Reporter. Cells were nucleofected with 
Tamoxifen-inducible I-SceI meganuclease and induced as noted in the figure. Percent of 
cells that undergo NHEJ repair and express mCherry are noted (+/−1STD). ***, p=0.0001, 
Two-tailed Student’s t-test. (i,j) Kinetics of the DNA repair in CCRF-CEM control and 
stable knockdown down T-ALL cells (TOX shRNA #2). The number of 53BP1 (i) and 
γH2A.X (j) foci per nucleus following 3Gγ irradiation are denoted. Each point represents 
data from a single cell and the black bars denote the median foci per cell (***, p<0.0001, 
Two-tailed Student’s t-test, >150 cells counted/condition). Box-and-whisker plots denote 
expression with the median 75% of samples and bars 90%.
Lobbardi et al. Page 32
Cancer Discov. Author manuscript; available in PMC 2018 November 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
